WO1999063967A1 - Enhanced intra vaginal devices - Google Patents
Enhanced intra vaginal devices Download PDFInfo
- Publication number
- WO1999063967A1 WO1999063967A1 PCT/NZ1999/000070 NZ9900070W WO9963967A1 WO 1999063967 A1 WO1999063967 A1 WO 1999063967A1 NZ 9900070 W NZ9900070 W NZ 9900070W WO 9963967 A1 WO9963967 A1 WO 9963967A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclodextrin
- progesterone
- intra
- polymer
- caprolactone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
- A61F6/142—Wirelike structures, e.g. loops, rings, spirals
- A61F6/144—Wirelike structures, e.g. loops, rings, spirals with T-configuration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Definitions
- the present invention relates to improvements in and/or relating to intra vaginal devices.
- polyesters include poly lactic acid, poly gly colic acid, poly ( ⁇ -caprolactone) and various co-polymers of lactide, glycolide and ⁇ -caprolactone.
- Pharmaceutical products utilising these polymers are typically formulated as microspheres, microcapsules, films, rods or blocks. Retention within a body cavity has been achieved by a number of methods, eg: the addition of dense fillers, injection or surgical implantation into muscle or subcutaneous areas.
- agents may be employed to enhance the absorption of agents across mucosal membranes and into the blood circulatory system.
- agents may be employed to enhance the absorption of agents across mucosal membranes and into the blood circulatory system.
- One such class of agents extensively utilised for the enhanced absorption of agents are the cyclodextrins.
- cyclodextrins examples include ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin and hydroxypropyl ⁇ -cyclodextrin.
- Devices utilising these absorption enhancing agents are typically formulated as microspheres, microcapsules, tablets or liquids.
- the present invention preferably relates to a device designed to deliver progesterone over an extended period of time (2 to 20 days) upon insertion into the vagina of mammals, eg: cattle, sheep, horses, pigs, goats, buffalo or deer.
- the device is preferably retained within the vagina preferably by means of a flexible geometric arrangement of arms with respect to a body portion.
- the present invention consists in a device for insertion into the vagina of a mammal, said device consisting of a matrix (preferably mouldable, eg: a polymer) containing both a cyclodextrin and an intra vaginally effective active ingredient.
- a matrix preferably mouldable, eg: a polymer
- intra vaginally effective active agent means any compound or composition or complex that by means of delivery into the vaginal cavity of a mammal can be absorbed systemically by the mammal therefrom so as to achieve or suppress some physiological effect.
- examples include progesterone (eg: for oestrus synchronisation and other purposes), and oxytocin (eg: for milk let down).
- cyclodextrin includes any suitable cyclodextrin or mixtures thereof.
- polymer in respect of carrying matrix of the cyclodextrin and intra vaginally effective active agent includes any suitable polymer and need not be restricted to the preferred polymers hereinafter discussed.
- the invention consists in an intra vaginal device having at least for a target species of appropriate size a form insertable and retainable in the vaginal tract, said device at least in part having a moulded matrix which includes both a cyclodextrin and an intra vaginally effective active agent.
- said matrix is at least in part (and preferably primarily) of a polymer or a mixture thereof.
- the polymer is poly ( ⁇ -caprolactone).
- the polymer is a starch-like polysaccharide.
- the polymer may be a blend of the options and/or a blend with another polymer.
- the cyclodextrin(s) comprise from 5 to 70% w / w .
- the active agent(s) comprise from 5 to 70% w / w .
- the agent is progesterone in the concentration of 5 to 70% w / w .
- the absorption enhancing agent is hydroxypropyl ⁇ -cyclodextrin in the concentration of 5 to 70% w / w .
- the device is of such geometry (eg; preferably of variable geometry) to facilitate retention in the vagina.
- the agent does not appear as a fine powder or crystals upon the surface of the device.
- the present invention is an intra vaginal device or insert for a target mammal species comprising or including an intra vaginally insertable, retainable and removable mass of at least primarily one or both of poly ( ⁇ -caprolactone) and a mouldable biodegradable starch-like polysaccharide, the mass by virtue of its resilience being of variable geometry which allows the intra vaginal insertion, retention and removal, wherein said mass includes therein sufficient progesterone therein such that for a target species a blood serum level of progesterone of greater than 2 ng / ml for a period of at least 5 days can follow intra vaginal insertion thereof and wherein after removal the mass is biodegradable after removal from the animal.
- target species is selected from cattle, sheep, horses, pigs, goats, buffalo and deer.
- said device or insert includes no supporting spine (eg; nylon or polyester).
- the progesterone inclusion is sufficient to deliver progesterone for a period from 2 to 20 days.
- said mass may include cyclodextrin.
- the present invention consists in the use or methods of use of such a device or any device of the present invention.
- the present invention also consists in a method of manufacture of an intra vaginal device which results in any device in accordance with the present invention.
- the invention consists in a method of manufacture of an intra vaginal device which comprises the step of including in a mouldable matrix forming material or polymer composition both a cyclodextrin and an intra vaginally effective agent.
- said active agent is a particulate solid.
- the cyclodextrin(s) comprise from 5 to 70% w / w .
- the active agent(s) comprise from 5 to 70% w / w .
- cyclodextrin is a particulate solid.
- said active agent and cyclodextrin are pre-mixed prior to association with the mouldable material or polymer composition.
- any one or more of the material/polymer, active agent and cyclodextrin are as herein defined.
- the invention consists in the use inter alia for animal group oestrus synchrony purposes of devices of the present invention.
- said use is intra vaginal use for a period of from 2 to 20 days and said device has a capability in the target species mammal of providing for at least 5 days (if intra vaginally inserted for at least about 5 days) a blood serum level of progesterone of greater than 2 ns / rnl .
- polymer(s) of the said mass can be moulded without use of conditions prejudicial to the pharmaceutical agent and any cyclodextrin (or for that matter, any other absorption enhancing agent) present.
- Silicone based intra vaginal inserts must include a spine of a material such as Nylon or stainless steel, over which the silicone is moulded, to maintain a configuration conducive to vaginal retention.
- the addition of large amounts of particulate material has been found to reduce the strength of the silicone such that the spine may rupture and protrude through the other silicone laminate.
- the invention also consists in a method of achieving with an animal (or group of animals) a blood serum level of greater than 2 ng / mI for a period of at least 5 days of progesterone, said method comprising inserting and retaining in the vagina of each animal for at least the 5 day period a device of any of the kinds of the present invention.
- said device has a loading of from 0.1 to 4 gms of progesterone for the target animals such as cattle, sheep, goats, deer, etc.
- said device has an impregnated matrix surface of from 15 to 200 cm 2 .
- the present invention also consists in a method of manufacture of an intra vaginal device which results in a device in accordance with the present invention, and/or vice versa.
- Figure 1 shows a device of variable geometry (the geometry being variable much in the way as discussed in WO 97/40776) but without a need for a spine of a dissimilar material although if desired that can optionally be present
- Figure 2 shows in vitro progesterone release
- FIG. 3 shows plasma progesterone concentration against time
- Figure 6 shows for silicone plasma progesterone concentration against time
- Figure 7 shows mass loss for poly ( ⁇ -caprolactone) formulations
- Figure 8 shows plasma progesterone concentration against time
- Figure 9 shows plasma progesterone concentration against time
- Figure 10 shows plasma progesterone concentration against time
- Figure 11 shows plasma progesterone concentration against time
- Figure 12 shows plasma progesterone concentration against time
- Figure 13 shows plasma progesterone concentration against time.
- the present invention relates to the discovery that polymers typified by poly ( ⁇ - caprolactone) or a starch like saccharide can be appropriately impregnated with an intra vaginally effective active agent such as progesterone (eg: in concentration of from 5% to 70% w/w) and an absorption enhancing agent such as hydroxypropyl ⁇ -cyclodextrin
- silicone type polymers Whilst conventional silicone type polymers may be used they are not normally considered biodegradable in a pasture environment as is, eg; poly ( ⁇ -caprolactone).
- the preferred device is wholly of the impregnated matrix which is poly ( ⁇ -caprolactone) impregnated with hydroxypropyl ⁇ -cyclodextrin in the concentration of 5 to 70% w/w.
- the wings 1 are resilient with respect to the body 2 and in an inj ection mode can be reduced to a form or assume a position in an applicator in a known manner which facilitates insertion after which the resilience deploys the wings 1 to such condition as is required for retention.
- a suitable source of poly ( ⁇ -caprolactone) is that product TONE P-767TM available from Union Carbide Specialty Polymers and Products, Danbury, Ct, USA.
- Starch- like polysaccharides that can likewise be impregnated and can be used for some or all of the device include MATER-BiTM available from Novamont, Italy.
- a suitable source of hydroxypropyl ⁇ -cyclodextrin is that product BETA W7 HP available from Wacker Chemicals Australia, Victoria, Australia.
- a preferred method of manufacture of the device is as follows: Polymer (poly)
- Figure 2 shows an in vitro cumulative progesterone release against the square- root-of-time (inserts manufactured from poly ( ⁇ -caprolactone) (thin line) or silicone (thick line)).
- Figure 3 shows an average plasma progesterone concentration against time following two rounds of vaginal treatment with a silicone insert of 134 cm 2 surface area
- Figure 6 shows plasma progesterone concentration against time following vaginal treatment for 7 days with a silicone insert of 134 cm 2 surface area ( ⁇ ), poly ( ⁇ - caprolactone) insert of 115 cm 2 surface area ( ⁇ ) or poly ( ⁇ -caprolactone) with lactose insert of 115 cm 2 surface area (o) (A final plasma sample was collected 6 hours after removal on day 7.
- Figure 7 shows the percentage of initial mass lost for various poly ( ⁇ - caprolactone) formulations stored in compost over time
- Poly ( ⁇ -caprolactone) ( ⁇ ) poly ( ⁇ -caprolactone) with 10% w / w progesterone ( ⁇ )
- poly ( ⁇ -caprolactone) with 43.8% w / w hydroxypropyl ⁇ -cyclodextrin and 10% w / w progesterone (*) or poly ( ⁇ -caprolactone) with 39.9% w / w ⁇ -cyclodextrin and 9.7% w / w progesterone (•).
- Figure 9 shows plasma progesterone concentration against time following vaginal treatment for 7 days with various inserts; CIDR cattle insert ( ⁇ ), poly ( ⁇ - caprolactone) with 10 % w / w progesterone ( ⁇ ), poly ( ⁇ -caprolactone) with 12.1 % w / w lactose and 10.47 %7 W progesterone (•), poly ( ⁇ -caprolactone) with 37.2 % w / w ⁇ - cyclodextrin and 10.3 % w / w progesterone (A), poly ( ⁇ -caprolactone) with 43.8 % w / w hydroxypropyl ⁇ -cyclodextrin and 10 % w / w progesterone (O) or poly ( ⁇ -caprolactone) with 39.9 % w / w ⁇ -cyclodextrin and 9.7 % w / w progesterone (x),
- Figure 10 shows plasma progesterone concentration against time following vaginal treatment for 7 days with various inserts; poly ( ⁇ -caprolactone) with 44 % w / w hydroxypropyl ⁇ -cyclodextrin and 10 % W progesterone ( ⁇ ), poly ( ⁇ -caprolactone) with 22 % W hydroxypropyl ⁇ -cyclodextrin and 10 %7 W progesterone (A), poly ( ⁇ - caprolactone) with 22 %7 W hydroxypropyl ⁇ -cyclodextrin and 10 %7 W progesterone and 22 %7 W lactose ( ⁇ ), poly ( ⁇ -caprolactone) with 11 %7 W hydroxypropyl ⁇ - cyclodextrin and 10 %7 W progesterone and 33 %7 W lactose (•),
- Figure 11 shows plasma progesterone concentration against time following vaginal treatment for 7 days with various inserts; poly ( ⁇ -caprolactone) with 5 %7 W hydroxypropyl ⁇ -cyclodextrin and 5 %7 W progesterone and 30 %7 W lactose ( ⁇ ), poly ( ⁇ -caprolactone) with 20 %7 W hydroxypropyl ⁇ -cyclodextrin and 10 %7 W progesterone and 30 % v 7 tt lactose (A), poly ( ⁇ -caprolactone) with 10 %7 W hydroxypropyl ⁇ - cyclodextrin and 10 %V W progesterone and 40 %7 W lactose ( ⁇ ), poly ( ⁇ -caprolactone) with 10 %7 W hydroxypropyl ⁇ -cyclodextrin and 5 %7 W progesterone and 35 %7 W lactose (•),
- Figure 12 shows plasma progesterone concentration against time following vaginal treatment for 7 days with various inserts; CIDR cattle insert (•), poly ( ⁇ - caprolactone) with 10 %7 W hydroxypropyl ⁇ -cyclodextrin and 10 %7 W progesterone and 50 % w / w poly ethylene oxide (A), Mater-Bi with 40 %7 W ⁇ -cyclodextrin and 10 %7 W progesterone ( ⁇ ), and
- Figure 13 shows plasma progesterone concentration against time following vaginal treatment for 15 days with a poly ( ⁇ -caprolactone) with 20 %7 W hydroxypropyl ⁇ -cyclodextrin and 10 %7 W progesterone and 30 %7 W lactose (A).
- a resilient mouldable or shapable "polymer" which is biodegradable is such that degradation of the impregnated matrix (but with a low residual active ingredient loading) will occur over time after removal from the animal after having served its purpose during an intra vaginal insertion of preferably from 2 to 20 days (eg; about 7 days). Minimal degradation (if any) occurs during the period of insertion.
- the device is wholly of the impregnated matrix which is poly ( ⁇ -caprolactone) impregnated with progesterone in the concentration of 5 to 70% w/w without any solid active pharmaceutical agent appearing as a fine powder or crystals on the surface of the device.
- the performance of the device while inserted and its effect upon withdrawal is substantially as discussed in WO 97/40776 but with the advantages of (i) biodegradability after removal from the animal and (ii) the preferred omission of a spine of resilient material.
- the preferred biodegradable polymers can be appropriately impregnated with an intra vaginally effective active agent such as progesterone (eg: in concentration of from 5% to 70% w/w) and an absorption enhancing agent such as hydroxypropyl ⁇ -cyclodextrin (eg: in concentrations of from 5% to 70% w/w) so as to provide appropriate release characteristics for the active agent over the period of intra vaginal retention.
- the preferred device is wholly of the impregnated matrix which is poly ( ⁇ - caprolactone) impregnated with hydroxypropyl ⁇ -cyclodextrin in the concentration of 5 to 70% w/w.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU45345/99A AU777673B2 (en) | 1998-06-05 | 1999-06-03 | Enhanced intra vaginal devices |
CA002334296A CA2334296A1 (en) | 1998-06-05 | 1999-06-03 | Enhanced intra vaginal devices |
JP2000553036A JP2002517429A (en) | 1998-06-05 | 1999-06-03 | Enhanced intravaginal device |
EP99928243A EP1085855A4 (en) | 1998-06-05 | 1999-06-03 | Enhanced intra vaginal devices |
US09/729,251 US6776164B2 (en) | 1998-06-05 | 2000-12-05 | Enhanced intravaginal devices |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ330596 | 1998-06-05 | ||
NZ330596A NZ330596A (en) | 1998-06-05 | 1998-06-05 | Intravaginal devices allowing for increased uptake of active ingredients |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/729,251 Continuation US6776164B2 (en) | 1998-06-05 | 2000-12-05 | Enhanced intravaginal devices |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999063967A1 true WO1999063967A1 (en) | 1999-12-16 |
Family
ID=19926758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NZ1999/000070 WO1999063967A1 (en) | 1998-06-05 | 1999-06-03 | Enhanced intra vaginal devices |
Country Status (7)
Country | Link |
---|---|
US (1) | US6776164B2 (en) |
EP (1) | EP1085855A4 (en) |
JP (1) | JP2002517429A (en) |
AU (1) | AU777673B2 (en) |
CA (1) | CA2334296A1 (en) |
NZ (1) | NZ330596A (en) |
WO (1) | WO1999063967A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1087773A1 (en) * | 1998-06-18 | 2001-04-04 | Dec Research | Vaginal active agent delivery procedures and formulations thereof |
WO2003065924A1 (en) * | 2002-02-08 | 2003-08-14 | Advanced Animal Technology Limited | Control of a biological function |
US6758840B2 (en) | 2000-04-20 | 2004-07-06 | Metris Therapeutics Limited | Drug delivery device |
WO2004091570A1 (en) * | 2003-04-17 | 2004-10-28 | Interag | Method of treatment |
WO2007090255A3 (en) * | 2006-02-06 | 2007-11-29 | Phb Ind Sa | Polymeric implant and a process for obtaining a polymeric implant |
US20100316691A2 (en) * | 2007-01-19 | 2010-12-16 | University Of Utah Research Foundation | Biodegradable intravaginal medical device for delivery of therapeutics |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL127129A (en) * | 1998-11-18 | 2004-06-01 | Ferring Bv | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
NZ519112A (en) * | 2002-05-22 | 2004-12-24 | Interag | Drug delivery device for administration of active agent to mammary gland cavity |
DE602004008912T3 (en) * | 2004-07-13 | 2012-09-13 | Bayer Schering Pharma Oy | Retarded release system with controlled initial delivery |
US8399012B2 (en) * | 2006-04-17 | 2013-03-19 | Kimberly-Clark Worldwide, Inc. | Degradable therapeutic delivery device |
JP5507467B2 (en) * | 2008-02-04 | 2014-05-28 | テバ ウィメンズ ヘルス インコーポレイテッド | Monolithic intravaginal rings containing progesterone and methods for their production and use |
DK2301595T3 (en) * | 2009-09-23 | 2014-04-07 | Dentsply Ih Ab | Translucent catheter and method for making such a catheter |
US9017310B2 (en) * | 2009-10-08 | 2015-04-28 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including microneedles |
US8882748B2 (en) * | 2009-10-08 | 2014-11-11 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including chemical permeation enhancers |
US9014799B2 (en) * | 2009-10-08 | 2015-04-21 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including electrically-actuated permeation enhancement |
CN101779994B (en) * | 2010-01-15 | 2011-03-23 | 王磊光 | Three-dimensional intrauterine device |
CA2789238C (en) * | 2010-03-09 | 2020-05-12 | Dignity Health | Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening |
WO2012058463A2 (en) | 2010-10-27 | 2012-05-03 | Dignity Health | Trimegestone (tmg) for treatment of preterm birth |
JP6285866B2 (en) | 2011-11-23 | 2018-02-28 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | Natural complex hormone replacement preparations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CN103156698A (en) * | 2011-12-19 | 2013-06-19 | 阿坝藏族羌族自治州科学技术研究院 | Ewe synchronized estrus vagina plugging device and preparation method |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9999720B2 (en) | 2012-09-27 | 2018-06-19 | Palo Alto Research Center Incorporated | Drug reconstitution and delivery device and methods |
US9005108B2 (en) | 2012-09-27 | 2015-04-14 | Palo Alto Research Center Incorporated | Multiple reservoir drug delivery device and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US9744341B2 (en) | 2013-01-15 | 2017-08-29 | Palo Alto Research Center Incorporated | Devices and methods for intraluminal retention and drug delivery |
US9297083B2 (en) | 2013-12-16 | 2016-03-29 | Palo Alto Research Center Incorporated | Electrolytic gas generating devices, actuators, and methods |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9801660B2 (en) | 2014-07-31 | 2017-10-31 | Palo Alto Research Center Incorporated | Implantable fluid delivery devices, systems, and methods |
US10278675B2 (en) | 2014-07-31 | 2019-05-07 | Palo Alto Research Center Incorporated | Implantable estrus detection devices, systems, and methods |
AU2016291095B2 (en) * | 2015-07-09 | 2021-04-29 | ULTl PHARMACEUTICALS LIMITED | A drug delivery device |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
AU201617347S (en) * | 2016-12-23 | 2017-01-23 | Jurox Pty Ltd | intravaginal device |
JP2023508606A (en) * | 2019-12-23 | 2023-03-02 | オーガスタ ユニバーシティ リサーチ インスティチュート,インコーポレイテッド | Progesterone preparations that induce ovulation and provide luteal phase support |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
US4732763A (en) * | 1978-10-17 | 1988-03-22 | Stolle Research And Development Corporation | Active/passive immunization of the internal female reproductive organs |
US4883785A (en) * | 1984-07-27 | 1989-11-28 | Chow Wing Sun | Complex of anti-fungal agent and cyclodextrin and method |
AU4501789A (en) * | 1988-10-03 | 1990-05-01 | Qlt Usa, Inc | Biodegradable in-situ forming implants |
AU7499091A (en) * | 1990-03-16 | 1991-10-10 | Schering Aktiengesellschaft Berlin Und Bergkamen | 9-chlor-prostaglandin-beta -cyclodextrin clathrates and their use as drugs |
US5116619A (en) * | 1988-08-30 | 1992-05-26 | Lee Roy Morgan | Vaginal progesterone tablet |
WO1993024154A1 (en) * | 1992-06-03 | 1993-12-09 | Fuisz Technologies, Ltd. | Biodegradable controlled release melt-spun delivery system |
EP0654484A2 (en) * | 1993-11-11 | 1995-05-24 | ASTA Medica Aktiengesellschaft | Pharmaceutical compositions containing inclusion compounds of thioctic or dihydroliponic acid with cyclodextrins and in granule form or in chewable or effervescent tablet form |
AU3846395A (en) * | 1994-11-07 | 1996-05-31 | Janssen Pharmaceutica N.V. | Compositions comprising carbazoles and cyclodextrins |
AU7637296A (en) * | 1995-11-14 | 1997-06-05 | Farmarc Nederland Bv | Complex of naproxen and beta-cyclodextrin |
WO1997034932A2 (en) * | 1996-03-20 | 1997-09-25 | British Technology Group Limited | Compositions containing starch excipients |
AU2715397A (en) * | 1996-05-01 | 1997-11-19 | Interag | Synchronising of animal oestrus and intra vaginal devices useful therein |
US5747058A (en) * | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
EP0845265A1 (en) * | 1995-08-15 | 1998-06-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Mucosal preparation containing physiologically active peptide |
AU8108198A (en) * | 1997-06-05 | 1998-12-21 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising cyclodextrins |
AU1696299A (en) * | 1997-11-21 | 1999-06-15 | Interag | Biodegradable intra vaginal devices |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3905360A (en) * | 1971-11-01 | 1975-09-16 | Alza Corp | Intrauterine device for governing the reproductive process |
US4578076A (en) * | 1984-03-20 | 1986-03-25 | The Population Council, Inc. | Medicated intracervical and intrauterine devices |
US5690954A (en) * | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
-
1998
- 1998-06-05 NZ NZ330596A patent/NZ330596A/en not_active IP Right Cessation
-
1999
- 1999-06-03 AU AU45345/99A patent/AU777673B2/en not_active Ceased
- 1999-06-03 JP JP2000553036A patent/JP2002517429A/en active Pending
- 1999-06-03 EP EP99928243A patent/EP1085855A4/en not_active Withdrawn
- 1999-06-03 WO PCT/NZ1999/000070 patent/WO1999063967A1/en active IP Right Grant
- 1999-06-03 CA CA002334296A patent/CA2334296A1/en not_active Abandoned
-
2000
- 2000-12-05 US US09/729,251 patent/US6776164B2/en not_active Expired - Lifetime
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4732763A (en) * | 1978-10-17 | 1988-03-22 | Stolle Research And Development Corporation | Active/passive immunization of the internal female reproductive organs |
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
US4883785A (en) * | 1984-07-27 | 1989-11-28 | Chow Wing Sun | Complex of anti-fungal agent and cyclodextrin and method |
US5116619A (en) * | 1988-08-30 | 1992-05-26 | Lee Roy Morgan | Vaginal progesterone tablet |
AU4501789A (en) * | 1988-10-03 | 1990-05-01 | Qlt Usa, Inc | Biodegradable in-situ forming implants |
AU7499091A (en) * | 1990-03-16 | 1991-10-10 | Schering Aktiengesellschaft Berlin Und Bergkamen | 9-chlor-prostaglandin-beta -cyclodextrin clathrates and their use as drugs |
WO1993024154A1 (en) * | 1992-06-03 | 1993-12-09 | Fuisz Technologies, Ltd. | Biodegradable controlled release melt-spun delivery system |
EP0654484A2 (en) * | 1993-11-11 | 1995-05-24 | ASTA Medica Aktiengesellschaft | Pharmaceutical compositions containing inclusion compounds of thioctic or dihydroliponic acid with cyclodextrins and in granule form or in chewable or effervescent tablet form |
AU3846395A (en) * | 1994-11-07 | 1996-05-31 | Janssen Pharmaceutica N.V. | Compositions comprising carbazoles and cyclodextrins |
US5747058A (en) * | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
EP0845265A1 (en) * | 1995-08-15 | 1998-06-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Mucosal preparation containing physiologically active peptide |
AU7637296A (en) * | 1995-11-14 | 1997-06-05 | Farmarc Nederland Bv | Complex of naproxen and beta-cyclodextrin |
WO1997034932A2 (en) * | 1996-03-20 | 1997-09-25 | British Technology Group Limited | Compositions containing starch excipients |
AU2715397A (en) * | 1996-05-01 | 1997-11-19 | Interag | Synchronising of animal oestrus and intra vaginal devices useful therein |
AU8108198A (en) * | 1997-06-05 | 1998-12-21 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising cyclodextrins |
AU1696299A (en) * | 1997-11-21 | 1999-06-15 | Interag | Biodegradable intra vaginal devices |
Non-Patent Citations (2)
Title |
---|
PHARMACEUTISCH WEEKBLAD, Vol. 14(4A), 1992, HERMENS W.A.J.J., "Delivery of Hormones: Some New Concepts", pages 253-257. * |
See also references of EP1085855A4 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1087773A1 (en) * | 1998-06-18 | 2001-04-04 | Dec Research | Vaginal active agent delivery procedures and formulations thereof |
EP1087773A4 (en) * | 1998-06-18 | 2002-03-13 | Interag | Vaginal active agent delivery procedures and formulations thereof |
US6758840B2 (en) | 2000-04-20 | 2004-07-06 | Metris Therapeutics Limited | Drug delivery device |
WO2003065924A1 (en) * | 2002-02-08 | 2003-08-14 | Advanced Animal Technology Limited | Control of a biological function |
WO2004091570A1 (en) * | 2003-04-17 | 2004-10-28 | Interag | Method of treatment |
WO2007090255A3 (en) * | 2006-02-06 | 2007-11-29 | Phb Ind Sa | Polymeric implant and a process for obtaining a polymeric implant |
CN101378733B (en) * | 2006-02-06 | 2013-03-06 | Phb工业有限公司 | Polymeric implant and a process for obtaining a polymeric implant |
US20100316691A2 (en) * | 2007-01-19 | 2010-12-16 | University Of Utah Research Foundation | Biodegradable intravaginal medical device for delivery of therapeutics |
Also Published As
Publication number | Publication date |
---|---|
US20010029357A1 (en) | 2001-10-11 |
NZ330596A (en) | 2001-02-23 |
EP1085855A1 (en) | 2001-03-28 |
AU777673B2 (en) | 2004-10-28 |
EP1085855A4 (en) | 2007-12-26 |
AU4534599A (en) | 1999-12-30 |
JP2002517429A (en) | 2002-06-18 |
US6776164B2 (en) | 2004-08-17 |
CA2334296A1 (en) | 1999-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6776164B2 (en) | Enhanced intravaginal devices | |
JP2977724B2 (en) | Complex substance for periodontal disease treatment | |
JP2571874B2 (en) | Protein microsphere composition | |
TWI537010B (en) | A fast dissolving pharmaceutical composition | |
EP0139286A2 (en) | Prolonged sustained-release preparations | |
MXPA01010094A (en) | Fast-dispersing dosage forms containing fish gelatin. | |
RU2412693C2 (en) | Delivery system | |
JP2001519787A (en) | Intravesical drug delivery system | |
TW201422254A (en) | Composition for immediate and extended release | |
EP0138216B1 (en) | Sustained-release ifn preparation for parenteral administration | |
AU2002235050B2 (en) | Geometry retainable devices for body cavities | |
CA2793485A1 (en) | A fast dissolving pharmaceutical composition | |
AU2002235050A1 (en) | Geometry retainable devices for body cavities | |
CA2311311C (en) | Biodegradable intra vaginal devices | |
FR2748205A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE CONTROLLED RELEASE OF INSOLUBLE ACTIVE SUBSTANCES | |
JP2001523515A5 (en) | ||
JP7248614B2 (en) | Contraceptives and related devices | |
NZ329229A (en) | Biodegradable intravaginal devices | |
JPH02212436A (en) | Sustained release base | |
JP2004502718A (en) | Suppositories and compositions comprising at least one polyethylene glycol | |
CA2438127A1 (en) | Geometry retainable devices for body cavities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 45345/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2334296 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09729251 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999928243 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999928243 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 45345/99 Country of ref document: AU |